Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • ABTECT
  • Pipeline
    • Overview
    • Patients
    • Obefazimod for UC
    • Obefazimod for Crohn’s
    • Obefazimod for RA
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • General Meeting
  • Contact Us
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

Fierce Biotech

March 7, 2023

Fierce Biotech Fundraising Tracker ’23

Pharmaceutical Technology

February 23, 2023

New pipeline agents expected to differentiate the UC market

GlobalCapital

February 23, 2023

Abivax raises EUR 130M in ABB amidst flurry of pharma deals (subscribers only)

European Biotechnology:

February 23, 2023

Abivax SA raises €130m to advance obefazimod to Phase III

ThePharmaLetter

February 23, 2023

Another oversubscribed financing for Abivax

  • 1
  • 2
© 2023 All rights reserved by ABIVAX | Website created by Stratégie et communication digitale : JLL CONSEIL Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Obefazimod for UC
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • General Meeting
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+